Back to Search Start Over

The economic impact of the introduction of universal rotavirus vaccination on rotavirus gastroenteritis related hospitalisations in children in Ireland.

Authors :
Murphy, Aileen
Kirby, Ann
De Blasio, Federica
Source :
Vaccine. Apr2023, Vol. 41 Issue 16, p2656-2663. 8p.
Publication Year :
2023

Abstract

• Introduction of the vaccine coincided with a reduced number of RVGE hospitalisations in public hospitals in Ireland amongst children under 5 years. While this effect was lagged (1 year), the impact is sustained. • Post vaccine, RVGE hospitalised patients were more likely to be older than 2 years with a lower length of stay on average. • Potential cost savings for the Irish healthcare system; the average annual reduction in hospitalisations (n = 492) with an estimated economic value of €0.92 million annually. Rotavirus gastroenteritis (RVGE), a vaccine preventable disease, remains a common cause of severe gastroenteritis in children globally. Ireland introduced the universal rotavirus vaccination to the national immunisation programme in 2016. In this paper the economic impact on RVGE related hospitalisations amongst children under 5 years is examined. Using national data from all Irish public hospitals, an Interrupted Times Series Analysis (ITSA) compares RVGE hospitalisations amongst children under 5 years, pre- and post-vaccine introduction. Costs are estimated and ITSA results are compared to the counterfactual to estimate the economic impact of the vaccine. A probit model examines patient characteristics pre- and post-vaccine introduction. Vaccine introduction coincided with lowered RVGE related hospitalisations. While this effect was delayed (1 year) there is evidence of a sustained impact. RVGE patients' post-vaccine introduction were likely to be over 2 years (p = 0.001) and length of stay was lower on average (p = 0.095). The counterfactual analysis revealed 492 RVGE hospitalisations were avoided on average annually since the introduction of the vaccine. This has an estimated economic value of €0.92 million per annum. Following the introduction of the rotavirus vaccine in Ireland, hospitalisations for RVGE decreased significantly and those hospitalised were older and with a reduced length of stay on average. This has the potential for significant cost savings for the Irish healthcare system. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
0264410X
Volume :
41
Issue :
16
Database :
Academic Search Index
Journal :
Vaccine
Publication Type :
Academic Journal
Accession number :
162920864
Full Text :
https://doi.org/10.1016/j.vaccine.2023.03.010